Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1313 - Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatment

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.
Application Number1313
Application NameBone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatment
Description of Medical ServiceThis proposal is for the provision of an MBS item for bone densitometry by DXA for women with breast cancer who receive, or are being considered for, treatment with aromatase inhibitors.
Description of Medical ConditionIn hormone receptor-positive breast cancer the proliferation of mammary carcinoma cells is dependent on oestrogen. Common therapies for hormone receptor positive breast cancer include aromatase inhibitors and tamoxifen. The aromatase inhibitors have a negative impact on bone density due to the inhibition of overall oestrogen production within the body.
Consultation Protocol3 October 2012 to 8 November 2012
Consultation Protocol (PDF 705 KB)
Consultation Protocol (Word 211 KB)
Final Protocol Final Protocol (PDF 611 KB)
Final Protocol (Word 240 KB)
ReportsFinal Assessment Report (PDF 877 KB)
Final Assessment Report (Word 1020 KB)
MSAC OutcomesPSD from November 2014
Public Summary Document (PDF 442 KB)
Public Summary Document (Word 279 KB)

PSD from July 2015
Public Summary Document (PDF 1401 KB)
Public Summary Document (Word 357 KB)

Meetings for this Application

Meeting TypeDate
PASC16 to 17 August 2012
13 to 14 December 2012
ESC 12 to 13 June 2014
11 to 12 June 2015
MSAC 26 to 28 November 2014
30 to 31 July 2015

Page currency, Latest update: 02 May, 2016